Self-administration of Psilocybin for the Acute Treatment of Migraine: A Case Report
- PMID: 37817818
- PMCID: PMC10561985
Self-administration of Psilocybin for the Acute Treatment of Migraine: A Case Report
Abstract
Background: Migraine is a common neurovascular disorder with a pathophysiology related to the serotonin (5-hydroxytryptamine; 5-HT) system. Pharmacologic modulation of 5-HT receptors has demonstrated efficacy in the acute treatment of migraines. Psilocybin, a classic psychedelic with 5-HT receptor activity, has demonstrated therapeutic potential in the management of neuropsychiatric conditions. To date, no reports have investigated the effect of psilocybin administered acutely during a migraine episode.
Case presentation: The case of a 33-year-old male patient with a history of migraines with aura, who had acute administration of oral psilocybin (in the form of the dried fruiting body of Psilocybe cubensis mushrooms) at migraine onset is presented. Headache intensity was rated hourly using the Numerical Rating Scale (NRS) and compared to three previous migraines. Profound reductions in headache intensity and emetic episodes were reported during the migraine treated acutely with oral psilocybin administration, compared to three previous migraines.
Discussion: The severe, disabling, and treatment-resistant nature of migraines warrants continued surveillance for novel pharmacologic interventions. The established congruous pathophysiology of migraine and pharmacology of psilocybin, via the 5-HT receptor system, positions psilocybin as a potential therapeutic target.
Conclusion: While this report highlights the potential role of psilocybin in the acute management of migraines, it is essential to note that it should not be considered a basis for guiding clinical practice at this point. Further research is necessary to establish the safety and efficacy of psilocybin as a treatment option for migraines.
Keywords: Psilocybin; headache; migraine; pharmacology; psychedelics; treatment.
Copyright © 2023. Matrix Medical Communications. All rights reserved.
Conflict of interest statement
DISCLOSURES: The author has no conflicts of interest relevant to the content of this article.
Figures

Similar articles
-
The Potential of Psychedelics for the Treatment of Episodic Migraine.Curr Pain Headache Rep. 2023 Sep;27(9):489-495. doi: 10.1007/s11916-023-01145-y. Epub 2023 Aug 4. Curr Pain Headache Rep. 2023. PMID: 37540398 Review.
-
Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin.Neurotherapeutics. 2021 Jan;18(1):534-543. doi: 10.1007/s13311-020-00962-y. Epub 2020 Nov 12. Neurotherapeutics. 2021. PMID: 33184743 Free PMC article. Clinical Trial.
-
A Proposal to Study the Safety and Efficacy of Psilocybe cubensis in Preclinical and Clinical Studies as a Therapeutic Alternative for Major Depressive Disorder.J Psychoactive Drugs. 2023 Nov-Dec;55(5):570-580. doi: 10.1080/02791072.2023.2246459. Epub 2023 Aug 18. J Psychoactive Drugs. 2023. PMID: 37594163
-
Clinical Features and Burden Scores in Japanese Pediatric Migraines With Brainstem Aura, Hemiplegic Migraine, and Retinal Migraine.J Child Neurol. 2020 Sep;35(10):667-673. doi: 10.1177/0883073820927840. Epub 2020 Jun 1. J Child Neurol. 2020. PMID: 32476572
-
Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.J Neurol Sci. 2022 Mar 15;434:120096. doi: 10.1016/j.jns.2021.120096. Epub 2021 Dec 16. J Neurol Sci. 2022. PMID: 34942586 Review.
Cited by
-
Mechanistic intersections between migraine and major depressive disorder.J Headache Pain. 2025 Jul 9;26(1):157. doi: 10.1186/s10194-025-02097-x. J Headache Pain. 2025. PMID: 40634879 Free PMC article. Review.
-
Psychedelics and Headache Disorders: an Update.Curr Neurol Neurosci Rep. 2025 Aug 9;25(1):57. doi: 10.1007/s11910-025-01446-2. Curr Neurol Neurosci Rep. 2025. PMID: 40782223 Review.
-
More Evidence is Needed Before Recommending Magic Mushrooms for the Treatment of Complicated Migraines.Innov Clin Neurosci. 2025 Mar 1;22(1-3):11. eCollection 2025 Jan-Mar. Innov Clin Neurosci. 2025. PMID: 40213118 Free PMC article. No abstract available.
-
Response to "More Evidence is Needed Before Recommending Magic Mushrooms for the Treatment of Complicated Migraines".Innov Clin Neurosci. 2025 Mar 1;22(1-3):11-12. eCollection 2025 Jan-Mar. Innov Clin Neurosci. 2025. PMID: 40213117 Free PMC article. No abstract available.
-
Classic Psychedelics in Pain Modulation: Mechanisms, Clinical Evidence, and Future Perspectives.ACS Chem Neurosci. 2025 Jun 18;16(12):2163-2177. doi: 10.1021/acschemneuro.5c00152. Epub 2025 Jun 6. ACS Chem Neurosci. 2025. PMID: 40474592 Free PMC article. Review.
References
-
- Stovner L, Hagen K, Jensen R et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193–210. - PubMed
-
- Stewart WF, Wood C, Reed ML et al. Cumulative lifetime migraine incidence in women and men. Cephalalgia. 2008;28(11):1170–1178. - PubMed
-
- Lipton RB, Bigal ME, Diamond M et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–349. - PubMed
-
- Goadsby PJ, Evers S. International Classification of Headache Disorders - ICHD-4 alpha. Cephalalgia. 2020;40(9):887–888. - PubMed
-
- Ferrari MD, Goadsby PJ, Burstein R et al. Migraine. Nat Rev Dis Primers. 2022;8(1):2. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous